Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.65 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.53 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26375267 | 0.88 | CRBN (0.51) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL22291951 | 0.87 | CRBN (0.65) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL16120058 | 0.86 | CRBN (0.67) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL31187529 | 0.86 | CRBN (0.67) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL25913651 | 0.85 | CRBN (0.68) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29149641 | 0.85 | CRBN (0.65) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL23729244 | 0.84 | CRBN (0.64) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL24822625 | 0.84 | CRBN (0.70) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20046832 | 0.84 | CRBN (0.70) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30992342 | 0.84 | CRBN (0.57) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238304-A1 | Small Molecule Degraders of DOT1L and Uses Thereof | NORTHWESTERN UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-01-26 | — | — | US | disclosed |
| US-11319316-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BIOVENTURES, LLC (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2022087335-A1 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20210395244-A1 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK) DEGRADATION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2021-12-23 | — | — | US | disclosed |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-11-25 | — | — | US | disclosed |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-10-14 | — | — | US | disclosed |
| US-20200331905-A1 | Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof | BIOVENTURES, LLC | 2020-10-22 | — | — | US | disclosed |
| US-10807977-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BIOVENTURES, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| WO-2020081880-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | BIOVENTURES, LLC (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20190135801-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-05-09 | — | — | US | disclosed |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-02-21 | — | — | US | disclosed |
| WO-2017184995-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BIOVENTURES, LLC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | RAB1A, SOS1, IQGAP1 | CRBN 3656/4885DDB1 2095/4885ALDH1A1 2378/4885 |
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | HIPK1, MCL1, HYPK | CRBN 421/4885DDB1 473/4885ALDH1A1 2875/4885 |
| US-20200331905-A1 | Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof | BCL2, BAX, BCL2L1 | CRBN 520/4885DDB1 134/4885ALDH1A1 3263/4885 |
| US-20210395244-A1 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK) DEGRADATION COMPOUNDS AND METHODS OF USE | MAP2K2, MAP2K1, MAP2K7 | CRBN 1094/4885DDB1 995/4885ALDH1A1 3186/4885 |
| US-20190135801-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BCL2, BAX, BCL2L1 | CRBN 520/4885DDB1 134/4885ALDH1A1 3263/4885 |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, NTRK1, ERBB2 | CRBN 194/4885DDB1 418/4885ALDH1A1 3928/4885 |
| US-20240238304-A1 | Small Molecule Degraders of DOT1L and Uses Thereof | DOT1L, STUB1, BAZ2B | CRBN 7/4885DDB1 1093/4885ALDH1A1 2743/4885 |
| US-11319316-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BCL2, BAX, BCL2L1 | CRBN 520/4885DDB1 134/4885ALDH1A1 3263/4885 |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885DDB1 480/4885ALDH1A1 4113/4885 |
| US-10807977-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BCL2, BAX, BCL2L1 | CRBN 520/4885DDB1 134/4885ALDH1A1 3263/4885 |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | TP53, MCL1, LIMS1 | CRBN 1187/4885DDB1 55/4885ALDH1A1 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.